Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

MLA

von Pawel, Joachim, et al. “Randomized Phase III Trial of Amrubicin versus Topotecan as Second-Line Treatment for Patients with Small-Cell Lung Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 32, no. 35, Dec. 2014, pp. 4012–19. EBSCOhost, https://doi.org/10.1200/JCO.2013.54.5392.

APA

von Pawel, J., Jotte, R., Spigel, D. R., O’Brien, M. E. R., Socinski, M. A., Mezger, J., Steins, M., Bosquée, L., Bubis, J., Nackaerts, K., Trigo, J. M., Clingan, P., Schütte, W., Lorigan, P., Reck, M., Domine, M., Shepherd, F. A., Li, S., & Renschler, M. F. (2014). Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 32(35), 4012–4019. https://doi.org/10.1200/JCO.2013.54.5392

Chicago

von Pawel, Joachim, Robert Jotte, David R Spigel, Mary E R O’Brien, Mark A Socinski, Jörg Mezger, Martin Steins, et al. 2014. “Randomized Phase III Trial of Amrubicin versus Topotecan as Second-Line Treatment for Patients with Small-Cell Lung Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32 (35): 4012–19. doi:10.1200/JCO.2013.54.5392.